New Immunotherapy Strategy Shows Promise in Fighting Cancer

CAMBRIDGE, MA / PALO ALTO, CA – A groundbreaking new strategy developed by researchers at MIT and Stanford University is offering a beacon of hope in the fight against cancer. The approach focuses on unleashing the power of the immune system to more effectively target and destroy tumor cells, potentially revolutionizing cancer treatment for countless patients.

Unlocking the Immune System’s Potential

For years, scientists have recognized the potential of immunotherapy – harnessing the body’s own defenses to combat cancer. However, many tumors develop mechanisms to evade immune detection, effectively putting up a “brake” on the immune response. The research team at MIT and Stanford has identified a key component of this braking system: sugar structures, known as glycans, found on the surface of cancer cells.

“Cancer cells are remarkably adept at hiding from the immune system,” explains Jessica Stark, a professor at MIT and lead author of the study published in Nature Biotechnology. “By understanding how they do this, we can develop strategies to remove the camouflage and allow the immune system to do its job.”

AbLecs: A Novel Approach to Cancer Immunotherapy

The researchers developed a novel class of molecules, dubbed “AbLecs,” designed to block these glycans. AbLecs are bifunctional, combining a lectin – a type of protein that binds to sugar – with a tumor-targeting antibody. This combination allows the AbLec to specifically bind to cancer cells and disrupt the glycan-mediated immune suppression.

In laboratory tests, AbLecs significantly enhanced the immune response against cancer cells. The team demonstrated this using Trastuzumab, an existing antibody used to treat breast, stomach, and colorectal cancers. By modifying the antibody with a lectin, they were able to redirect immune cells to attack and destroy cancer cells.

Promising Results in Preclinical Studies

The effectiveness of AbLecs was tested in mouse models engineered to express human Siglec receptors, which play a role in immune regulation. The results were striking: treatment with AbLecs led to a significant reduction in lung metastasis, indicating a powerful anti-cancer effect.

“We’ve created a new type of protein therapeutic that can block glycan-based immune checkpoints and amplify anti-cancer immune responses,” Stark stated. “The versatility of this approach is particularly exciting, as we can adapt it to target different glycans and various types of cancer.”

Looking Ahead: Clinical Trials on the Horizon

The researchers have founded a company, Valora Therapeutics, to further develop this technology and translate it into clinical applications. They anticipate initiating clinical trials within the next two to three years, offering a potential new treatment option for patients battling a wide range of cancers.

The broader impact: Cancer remains a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, according to the World Health Organization. Innovative approaches like this one are crucial in the ongoing effort to improve cancer survival rates and quality of life for patients. The potential to broaden the effectiveness of immunotherapy, a treatment already showing promise, could represent a significant step forward in oncology.

If you have information relevant to this story, please contact us.